RESUMEN
Pulmonary artery intimal sarcoma (PAIS) is a rare and aggressive malignancy originating from the intimal layer of the pulmonary artery with poor prognosis due to its aggressive nature. The management of PAIS poses both diagnostic and therapeutic challenges. It presents with nonspecific symptoms and is often misdiagnosed as pulmonary embolism. While surgical resection is the primary treatment modality, the role of adjuvant chemotherapy and radiotherapy remains uncertain. However, given the high recurrence rate, adjuvant chemotherapy and/or radiotherapy have been utilized in a limited number of case reports. We present the case of a 46-year-old woman who was diagnosed with PAIS and underwent surgical resection followed by adjuvant chemotherapy (ChT) and radiotherapy (RT), demonstrating good tolerance to this multimodal treatment approach.
Asunto(s)
Arteria Pulmonar , Sarcoma , Túnica Íntima , Neoplasias Vasculares , Humanos , Femenino , Persona de Mediana Edad , Arteria Pulmonar/patología , Sarcoma/terapia , Sarcoma/patología , Neoplasias Vasculares/terapia , Neoplasias Vasculares/patología , Neoplasias Vasculares/diagnóstico por imagen , Terapia Combinada , Túnica Íntima/patología , Quimioterapia Adyuvante , Radioterapia Adyuvante , Diagnóstico DiferencialAsunto(s)
Codón sin Sentido/genética , Enzima Desubiquitinante CYLD/genética , Síndromes Neoplásicos Hereditarios/genética , Neoplasias Cutáneas/genética , Niño , Femenino , Humanos , Persona de Mediana Edad , Síndromes Neoplásicos Hereditarios/diagnóstico , Síndromes Neoplásicos Hereditarios/patología , Linaje , Fenotipo , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/patología , Turquía/epidemiologíaRESUMEN
Stereotactic body radiotherapy is a highly effective form of radiation therapy for palliation of bone metastases, but it can also lead to rare but severe side effects, such as myonecrosis. According to the literature, the incidence of myonecrosis after stereotactic body radiotherapy is low and mostly dose dependent. It is crucial to consider the potential impact of immunotherapy and other systemic therapies in the assessment. The course of radiation myonecrosis can vary, and corticosteroids or vascular endothelial growth factor inhibitors may potentially play a role in its treatment. Herein, we report two patients presenting with myonecrosis after stereotactic body radiotherapy for bone metastasis.
Asunto(s)
Neoplasias Óseas , Necrosis , Radiocirugia , Humanos , Radiocirugia/efectos adversos , Necrosis/etiología , Neoplasias Óseas/secundario , Neoplasias Óseas/radioterapia , Masculino , Anciano , Persona de Mediana Edad , Femenino , Enfermedades Musculares/etiología , Traumatismos por Radiación/etiología , Músculo Esquelético/patologíaRESUMEN
BACKGROUND: Interferons are molecules with antiviral effects, which have been used for the treatment of verruca for many years. AIMS: To determine if sublesional interferon (IFN)-alpha injection offers an effective alternative treatment for common warts. METHODS: We compared the results of single-dose sublesional IFN application in different types of verruca and with placebo for the treatment of single verruca plantaris lesions. In total, 53 patients (mean age 22.6 years) were enrolled in the study. Of these, 45 patients received a single sublesional injection of 4.5 MU IFN-alpha2a (three study groups), and eight patients with single verruca plantaris lesions were injected with physiological saline as placebo (control group). As local anaesthesia, liquid nitrogen was sprayed only on to the injection site for 3-4 s. The injection was made directly under the lesion through the border of the lesion, at with approximately a 45 degrees angle from healthy skin. RESULTS: At the 12-month follow-up in the group of patients with single verruca plantaris, there were 19 complete cures (7.2%) and 2 partial responses (8.3%), and 3 patients (12.5%) had no response. In the control group, only 2 patients (25%) had a partial response to treatment. CONCLUSIONS: These results suggest that a single sublesional dose of 4.5 MU IFN-alpha may be of value in the treatment of patients with verruca, especially in those with single verruca plantaris lesions.
Asunto(s)
Antivirales/administración & dosificación , Dermatosis del Pie/tratamiento farmacológico , Interferón-alfa/administración & dosificación , Verrugas/tratamiento farmacológico , Acetaminofén/uso terapéutico , Adolescente , Adulto , Analgésicos no Narcóticos/uso terapéutico , Antivirales/uso terapéutico , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Dermatosis de la Mano/tratamiento farmacológico , Humanos , Inyecciones Subcutáneas , Interferón alfa-2 , Interferón-alfa/uso terapéutico , Masculino , Estudios Prospectivos , Proteínas Recombinantes , Método Simple Ciego , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: There are many therapeutic alternatives for the management of onychocryptosis. Generally in severe cases, surgical approaches are preferred. OBJECTIVE: The aim of this study was to introduce the new surgical method that treats onychocryptosis without inducing a permanent injury to the matrix. MATERIALS AND METHODS: Twenty-two patients with 30 cases of onychocryptosis were treated by unilateral soft tissue resection combined with partial nail plate avulsion technique without permanent matricectomy. RESULTS: Complete recovery was attained in 25 (83.3%) of cases. No complication was observed. CONCLUSION: The most important advantage of this method was on the nail matrix. No permanent injury is incurred on the matrix.
Asunto(s)
Uñas Encarnadas/cirugía , Adolescente , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Uñas Encarnadas/patología , Resultado del TratamientoRESUMEN
Behçet's disease is a multisystemic disease characterized by activation and remission periods. The etiopathogenesis is not exactly known; a genetic defect in the immunoregulatory system induced by infectious agents, like viruses and bacteria, is thought to cause the disease. In this study, we examine the serum levels of vitamins A, C, and E, beta-carotene, selenium, and zinc in Behçet's disease patients and investigate the relationship between these serum levels and the activation of the disease. We conclude that adding vitamin E to the treatment of Behçet's disease patients and its effects on the prognosis of the disease need to be further investigated by controlled studies.